|
1
|
World Health Organization; International
Agency for Research on Cancer: Cervical Cancer - Estimated
Incidence. Mortality and Prevalence Worldwide in. 2012.http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx?cancer=cervix
|
|
2
|
National Comprehensive Cancer Network:
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines).
Cervical Cancer. Version 1. 2013.http://www.alabmed.com/uploadfile/2014/0221/20140221105002791.pdfAccessed.
September 11–2015
|
|
3
|
National Cancer Institute: Cervical cancer
treatment. http://www.cancer.gov/types/cervical/patient/cervical-treatment-pdqAccessed.
September 11–2015
|
|
4
|
Monk BJ, Sill MW, McMeekin DS, Cohn DE,
Ramondetta LM, Boardman CH, Benda J and Cella D: Phase III trial of
four cisplatin-containing doublet combination in stage IVB,
recurrent or persistent cervical carcinoma: A gynecologic oncology
group study. J Clin Oncol. 27:4649–4655. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Thigpen JT: The role of chemotherapy in
the management of carcinoma of the cervix. Cancer J. 9:425–432.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tattersall MH, Ramirez C and Coppleson M:
A randomized trial of adjuvant chemotherapy after radical
hysterectomy in stage Ib-IIa cervical cancer patients with pelvic
lymph node metastasis. Gynecol Oncol. 46:176–181. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Takeshima N, Umayahara K, Fujiwara K,
Hirai Y, Takizawa K and Hasumi K: Treatment results of adjuvant
chemotherapy after radical hysterectomy for intermediate-and
high-risk stage IB-IIA cervical cancer. Gynecol Oncol. 103:618–622.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lahousen M, Haas J, Pickel H, Hackl A,
Kurz C, Ogris H, Stummvoll W and Winter R: Chemotherapy versus
radiotherapy versus observation for high-risk cervical carcinoma
after radical hysterectomy: A randomized, prospective, multicenter
trial. Gynecol Oncol. 73:196–201. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kato R, Hasegawa K, Achiwa Y, Okamoto H,
Torii Y, Oe S and Udagawa Y: Predicting nedaplatin sensitivity of
cervical cancer using the histoculture drug response assay. Eur J
Gynaecol Oncol. 32:381–386. 2011.PubMed/NCBI
|
|
10
|
Yamamoto K, Kokawa K, Nishimura R,
Hasegawa K, Konishi I, Saji F, Nishida M, Noguchi H and Takizawa K:
Phase I study of combination chemotherapy with irinotecan
hydrochloride and nedaplatin for cervical squamous cell carcinoma:
Japanese gynecologic oncology group study. Oncol Rep. 21:1005–1009.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Watanabe Y, Nakai H, Etoh T, Kanemura K,
Tsuji I, Ishizu A and Hoshiai H: Feasibility study of docetaxel and
nedaplatin for recurrent squamous cell carcinoma of the uterine
cervix. Anticancer Res. 28:2385–2388. 2008.PubMed/NCBI
|
|
12
|
Detre S, Jotti Saclani G and Dowsett M: A
‘quickscore’ method for immunohistochemical semiquantitation:
Validation for oestrogen receptor in breast carcinomas. J Clin
Pathol. 48:876–878. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH,
Kim JH, Song HY, Shin JH, Jung HY, Lee GH, et al: ERCC1 predicting
chemoradiation resistance and poor outcome in oesophageal cancer.
Eur J Cancer. 44:54–60. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vescio RA, Connors KM, Kubota T and
Hoffman RM: Correlation of histology and drug response of human
tumors grown in negative-state three-dimensional histoculture and
in nude mice. Proc Natl Acad Sci USA. 88:5163–5166. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hoffman RM: In vitro assay for
chemotherapy sensitivity. Crit Rev Oncol Hematol. 15:99–111. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ohie S, Udagawa Y, Kozu A, Komuro Y, Aoki
D, Nozawa S, Moossa AR and Hoffman RM: Cisplatin sensitivity of
ovarian cancer in the histoculture drug response assay correlates
to clinical response to combination chemotherapy with cisplatin,
doxorubicin and cyclophosphamide. Anticancer Res. 20:2049–2054.
2000.PubMed/NCBI
|
|
17
|
Yoshimasu T, Ohta F, Oura S, Tamaki T,
Shimizu Y, Naito K, Kiyoi M, Hirai Y, Kawago M and Okamura Y:
Histoculture drug response assay for gefitinib in non-small-cell
lung cancer. Gen Thorac Cardiovasc Surg. 57:138–143. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fujita Y, Hiramatsu M, Kawai M, Nishimura
H, Miyamoto A and Tanigawa N: Histoculture drug response assay
predicts the postoperative prognosis of patients with esophageal
cancer. Oncol Rep. 21:499–505. 2009.PubMed/NCBI
|
|
19
|
Furukawa T, Kubota T and Hoffman RM:
Clinical application of the histoculture drug response assay. Clin
Cancer Res. 1:305–311. 1995.PubMed/NCBI
|
|
20
|
Furukawa T, Kubota T, Tanino H, et al:
Chemosensitivity of breast cancer lymph node metastasis compared to
the primary tumor from individual patients tested in the
histoculture drug response assay. Anticancer Res. 20:3657–3658.
2000.PubMed/NCBI
|
|
21
|
Tanino H, Oura S, Hoffman RM, et al:
Acquisition of multidrug resistance in recurrent breast cancer
demonstrated by the histoculture drug response assay. Anticancer
Res. 21:4083–4086. 2001.PubMed/NCBI
|
|
22
|
Hirano Y, Kageyama S, Ushiyama T, Suzuki K
and Fujita K: Clinical usefulness of chemotherapy based on an in
vitro chemosensitivity test in urothelial cancer patients.
Anticancer Res. 21:4061–4066. 2001.PubMed/NCBI
|
|
23
|
Singh B, Li R, Xu LI, et al: Prediction of
survival in patients with head and neck cancer using the
histoculture drug response assay. Head Neck. 24:437–442. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Morioka H, Yabe H, Morii T, Yamada R, Kato
S, Yuasa S and Yano T: In vitro chemosensitivity of human soft
tissue sarcoma. Anticancer Res. 21:4147–4151. 2001.PubMed/NCBI
|
|
25
|
Nakata S, Aoki D, Ohie S, Horiguchi M,
Suzuki N, Kanasugi M, Susumu N, Udagawa Y and Nozawa S:
Chemosensitivity testing of ovarian cancer using the histoculture
drug response assay: Sensitivity to cisplatin and clinical
response. Int J Gynecol Cancer. 15:445–452. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kanasugi M, Aoki D, Suzuki N, Susumu N,
Nakata S, Horiguchi M, Udagawa Y and Nozawa S: Sensitivity to
cisplatin determined by the histoculture drug response assay and
clinical response of endometrial cancer. Int J Gyenecol Cancer.
16:409–415. 2006. View Article : Google Scholar
|
|
27
|
Bonetti A, Zaninelli M, Rodella S, Molino
A, Sperotto L, Piubello Q, Bonetti F, Nortilli R, Turazza M and
Cetto GL: Tumor proliferative activity and response to first-line
chemotherapy in advanced breast carcinoma. Breast Cancer Res Treat.
38:289–297. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
O'Reilly SM, Camplejohn RS, Rubens RD and
Richards MA: DNA flow cytometry and response to preoperative
chemotherapy for primary breast cancer. Eur J Cancer. 28:681–683.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sultana H, Kigawa J, Kanamori Y, Itamochi
H, Oishi T, Sato S, Kamazawa S, Ohwada M, Suzuki M and Terakawa N:
Chemosensitivity and p53-Bax pathway-mediated apoptosis in patients
with uterine cervical cancer. Ann Oncol. 14:214–219. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Costa S, Terzano P, Santini D, Ceccarelli
C, Martoni A, Angelelli B, Panetta A, Bovicelli A, Cristiani P,
Lipponen P, et al: Neoadjuvant chemotherapy in cervical carcinoma:
Regulators of cell cycle, apoptosis, and proliferation as
determinants of response to therapy and disease outcome. Am J Clin
Pathol. 116:729–737. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Righetti SC, Della Torre G, Pilotti S,
Ménard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C,
Cornarotti M, Oriana S, et al: A comparative study of p53 gene
mutations, protein accumulation and response to cisplatin-based
chemotherapy in advanced ovarian carcinoma. Cancer Res. 56:689–693.
1996.PubMed/NCBI
|
|
32
|
Sato S, Kigawa J, Minagawa Y, Okada M,
Shimada M, Takahashi M, Kamazawa S and Terakawa N: Chemosensitivity
and p53-dependent apoptosis in epithelial ovarian carcinoma.
Cancer. 86:1307–1313. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lu X and Feki A: Phenotypic features with
p53 alterations related to human papillomavirus and prognostic
evaluation in cervical cancer. Int J Gynecol Cancer. 16:708–717.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Soussi T, Dehouche K and Béroud C: P53
website and analysis of p53 gene mutations in human cancer: forging
a link between epidemiology and carcinogenesis. Hum Mutat.
15:105–113. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kraiss S, Spiess S, Reihsaus E and
Montenarh M: Correlation of metabolic stability and altered
quaternary structure of oncoprotein p53 with cell transformation.
Exp Cell Res. 192:157–164. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Banin S, Moyal L, Shieh S, Taya Y,
Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y
and Ziv Y: Enhanced phosphorylation of p53 by ATM in response to
DNA damage. Science. 281:1674–1677. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hirao A, Kong YY, Matsuoka S, et al: DNA
damage-induced activation of p53 by the checkpoint kinase Chk2.
Science. 287:1824–1827. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Reed JC: Bcl-2 and the regulation of
programmed cell death. J Cell Biol. 124:1–6. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pillai MR, Jayaprakash PG and Nair MK:
Bcl-2 immunoreactivity but not p53 accumulation associated with
tumour response to radiotherapy in cervical carcinoma. J Cancer Res
Clin Oncol. 125:55–60. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rajkumar T, Rajan S, Baruah RK, Majhi U,
Selvaluxmi G and Vasanthan A: Prognostic significance of Bcl-2 and
p53 protein expression in stage IIB and IIIB squamous cell
carcinoma of the cervix. Eur J Gynaecol Oncol. 19:556–560.
1998.PubMed/NCBI
|
|
41
|
Wootipoom V, Lekhyananda N, Phungrassami
T, Boonyaphiphat P and Thongsuksai P: Prognostic significance of
Bax, Bcl-2 and p53 expressions in cervical squamous cell carcinoma
treated by radiotherapy. Gynecol Oncol. 94:636–642. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pezzella F, Turley H, Kuzu I, et al: Bcl-2
protein in non-small cell lung carcinoma. N Engl J Med.
329:690–694. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Joensuu H, Pylkkänen L and Toikkanen S:
Bcl-2 protein expression and long-term survival in breast cancer.
Am J Pathol. 145:1191–1198. 1994.PubMed/NCBI
|
|
44
|
Diebold J, Baretton G, Felchner M, et al:
Bcl-2 expression, p53 accumulation, and apoptosis in ovarian
carcinoma. Am J Clin Pathol. 105:341–349. 1996.PubMed/NCBI
|
|
45
|
Crawford RA, Caldwell C, Iles RK, et al:
Prognostic significance of the bcl-2 apoptotic family of proteins
in primary and recurrent cervical cancer. Br J Cancer. 78:210–214.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Itoi T, Yamana K, Bilim V, Takahashi K and
Tomita F: Impact of frequent bcl-2 expression on better prognosis
in renal cell carcinoma patients. Br J Cancer. 90:200–205. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Saito T, Takehara M, Tanaka R, Lee R,
Horie M, Wataba K, Ito E and Kudo R: Correlation between
responsiveness of neoadjuvant chemotherapy and apoptosis-associated
proteins for cervical adenocarcinoma. Gynecol Oncol. 92:284–292.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Munakata S, Watanabe O, Ohashi K and
Morino H: Expression of Fas ligand and bcl-2 in cervical carcinoma
and their prognostic significance. Am J Clin Pathol. 123:879–885.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Padovan P, Salmaso R, Marchetti M and
Padovan R: Prognostic value of bcl-2, p53 and Ki-67 in invasive
squamous carcinoma of the uterine cervix. Eur J Gynecol Oncol.
21:267–272. 2000.
|
|
50
|
Mukherjee G, Freeman A, Moore R,
Kumaraswamy, Devi KU, Morris LS, Coleman N, Dilworth S, Prabhakaran
PS and Stanley MA: Biologic factors and response to radiotherapy in
carcinoma of the cervix. Int J Gynecol Cancer. 11:187–193. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Gown AM and Willingham MC: Improved
detection of apoptotic cells in archival paraffin sections:
Immunohistochemistry using antibodies to cleaved caspase 3. J
Histochem Cytochem. 50:449–454. 2000. View Article : Google Scholar
|
|
52
|
Levine EL, Renehan A, Gossiel R, Davidson
SE, Roberts SA, Chadwick C, Wilks DP, Potten CS, Hendry JH, Hunter
RD, et al: Apoptosis, intrinsic radiosensitivity and prediction of
radiotherapy response in cervical carcinoma. Radiother Oncol.
37:1–9. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Levine EL, Davidson SE, Roberts SA,
Chadwick CA, Potten CS and West CM: Apoptosis as predictor of
response to radiotherapy in cervical carcinoma. Lancet.
344:4721994. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kim JY, Cho HY, Lee KC, Hwang YJ, Lee MH,
Roberts SA and Kim CH: Tumor apoptosis in cervical cancer: Its role
as a prognostic factor in 42 radiotherapy patients. Int J Cancer.
96:305–312. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Tomozawa S, Tsuno NH, Sunamio E, Hatano K,
Kitayama J, Osada T, Saito S, Tsuruo T, Shibata Y and Nagawa H:
Cyclooxygenase-2 overexpression correlates with tumor recurrence,
especially haematogenous metastasis of colorectal cancer. Br J
Cancer. 83:324–328. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Madaan S, Abel PD, Chaudhary KS, Hewitt R,
Stott MA, Stamp GW and Lalani EN: Cytoplasmic induction and
overexpression of cyclooxygenase-2 in human prostate cancer:
Implication for prevention and treatment. BJU Int. 86:736–741.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Hwang D, Skollard D, Byerne J and Levine
E: Expression of Cyclooxygenase-1 and cyclooxygenase-2 in human
breast cancer. J Natl Cancer Inst. 90:455–460. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Achiwa H, Yatabe Y, Hida T, Kuroishi T,
Kozaki K, Nakamura S, Ogawa M, Sugiura T, Mitsudomi T and Takahashi
T: Prognostic significance of elevated cyclooxygenase-2 expression
in primary resected lung adenocarcinomas. Clin Cancer Res.
5:1001–1005. 1999.PubMed/NCBI
|
|
59
|
Sheehan KM, Sheahan K, O'Donoghue DP,
MacSweeney F, Conroy RM, Fitzgerald DJ and Murray FE: The
relationship between Cyclooxygenase-2 expression and colorectal
cancer. JAMA. 282:1254–1257. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Liu XH, Yao S, Kirschenbaum A and Levine
AC: NS398, a selective cyclooxygenase-2 inhibitor, induces
apoptosis and down regulation bcl-2 expression in LNCaP cells.
Cancer Res. 58:4254–4249. 1998.
|
|
61
|
Ferrandina G, Lauriola L, Distefana MG,
Zannoni GF, Gessi M, Legge F, Maggiano N, Mancuso S, Capelli A,
Scambia G and Ranelletti FO: Increased cyclooxygenase-2 expression
is associated with chemotherapy resistance and poor survival in
cervical cancer patients. J Clin Oncol. 20:973–981. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
de Laat WL, Appeldoorn E, Jaspers NG and
Hoeijmakers JH: DNA structural elements required for ERCC1-XPF
endonuclease activity. J Biol Chem. 273:7835–7842. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Lord RV, Brabender J, Gandara D, Alberola
V, Camps C, Domine M, Cardenal F, Sánchez JM, Gumerlock PH, Tarón
M, et al: Low ERCC1 expression correlates with prolonged survival
after cisplatin plus gemcitabine chemotherapy in non-small cell
lung cancer. Clin Cancer Res. 8:2286–2291. 2002.PubMed/NCBI
|
|
64
|
Azuma K, Komohara Y, Sasada T, Terazaki Y,
Ikeda J, Hoshino T, Itoh K, Yamada A and Aizawa H: Excision repair
cross-complementation group 1 predicts progression-free and overall
survival in non-small cell lung cancer patients treated with
platinum-based chemotherapy. Cancer Sci. 98:1336–1343. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Olaussen KA, Dunant A, Fouret P, et al:
DNA repair by ERCC1 in non-small-lung cancer and cisplatin-based
adjuvant chemotherapy. N Engl J Med. 355:983–991. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Metzger R, Leichman CG, Danenberg KD, et
al: ERCC1 mRNA levels complement thymidylate synthase mRNA levels
in predicting response and survival for gastric cancer patients
receiving combination cisplatin and fluorouracil chemotherapy. J
Clin Oncol. 16:309–316. 1998.PubMed/NCBI
|
|
67
|
Kim MK, Cho KJ, Kwan GY, et al: ERCC1
predicting chemoradiation resistance and poor outcome in
oesophageal cancer. Eur J Cancer. 44:54–60. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Bellmunt J, Paz-Ares L, Cuello M, Cecere
FL, Albiol S, Guillem V, Gallardo E, Carles J, Mendez P, de la Cruz
JJ, et al: Gene expression of ERCC1 as a novel prognostic marker in
advanced bladder cancer patients receiving cisplatin-based
chemotherapy. Ann Oncol. 18:522–528. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Steffensen KD, Waldstrøm M and Jakobsen A:
The relationship of platinum resistance and ERCC1 protein
expression in epithelial ovarian cancer. Int J Gynecol Cancer.
19:820–825. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Scheil-Bertram S, Tylus-Schaaf P, du Bois
A, Harter P, Oppitz M, Ewald-Riegler N and Fisseler-Eckhoff A:
Excision repair cross-complementation group 1 protein
overexpression as a predictor of poor survival for high-grade
serous ovarian adenocarcinoma. Gynecol Oncol. 119:325–331. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Park JS, Jeon EK, Chun SH, Won HS, Lee A,
Hur SY, Lee KH, Bae SN, Yoon SC and Hong SH: ERCC1 (excision repair
cross-complementation group 1) expression as a predictor for
response of neoadjuvant chemotherapy for FIGO 2B uterine cervix
cancer. Gynecol Oncol. 120:275–279. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Hasegawa K, Kato R, Torii Y, Ichikawa R,
Oe S and Udagawa Y: The relationship between ERCC1 expression and
clinical outcome in patients with FIGO stage I to stage II uterine
cervical adenocarcinoma. Int J Gynecol Cancer. 21:1479–1485. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Costa S, Terzano P, Bovicelli A, Martoni
A, Angelelli B, Santini D, Ceccarelli C, Lipponen P, Erzén M,
Syrjänen S and Syrjänen K: CD44 isoform 6 (CD44v6) is a prognostic
indicatior of the response to neoadjuvant chemotherapy in cervical
cancer. Gynecol Oncol. 80:67–73. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Chung HH, Kim MK, Kim JW, Park NH, Song
YS, Kang SB and Lee HP: XRCC1 R399Q polymorphism is associated with
response to platinum-based neoadjuvant chemotherapy in bulky
cervical cancer. Gynecol Oncol. 103:1031–1037. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Faried LS, Faried A, Kanuma T, Sano T,
Nakazato T, Tamura T, Kuwano H and Minegishi T: Predictive and
prognostic role of activated mammalian target of rapamycin in
cervical cancer treated with cisplatin-based neoadjuvant
chemotherapy. Oncol Rep. 16:57–63. 2006.PubMed/NCBI
|
